Market Overview

Veeva Vault Submissions Publishing Now Available to Help Accelerate Submission Delivery


Seamlessly incorporate publishing activities within Veeva Vault RIM
for end-to-end submission development

(NYSE:VEEV) today announced the availability of Veeva
Vault Submissions Publishing
, a new cloud application in the Veeva
Vault RIM Suite
to unify publishing and submission document
authoring. Vault Submissions Publishing automatically publishes and
validates documents as they are authored and approved so regulatory
teams complete work earlier. Now life sciences organizations can speed
submission delivery with seamless traceability, from planning through
transmission to the health authority gateway, within a single unified
RIM platform.

Submission planning, content management, publishing, validation, and
transmission are typically completed in separate systems, creating
inefficiency when documents are transferred internally. System silos
also delay publishing until the submission documents are finalized, when
timelines are most pressing.

"Veeva Vault Submissions Publishing allows us to bring together
publishing activities with document planning, authoring, and approval to
streamline the entire submission development process," said Shelly
Plapp, director of regulatory operations at Melinta Therapeutics. "Now
we can conduct publishing activities earlier and complete submissions
much faster."

Veeva Vault Submissions Publishing enables a continuous publishing
process for sponsors to finish publishing steps sooner so validation
issues are identified and fixed faster. It also allows teams to
eliminate moving documents between multiple systems and reduce the
number of document transfers to one – when the dossier is transmitted
directly to a health authority.

"Veeva Vault Submissions Publishing unifies regulatory activities within
the Vault RIM Suite and across the submission development lifecycle,"
said John Lawrie, vice president of Veeva Vault RIM. "When there's a
product-related change, Vault RIM customers can trace impacted
registrations to the corresponding submissions, authored content, and
published output all in a single system."

The Vault RIM Suite provides fully integrated RIM capabilities to manage
product registrations, health authority correspondence and commitments,
submission documents, and published dossiers on a single cloud platform.
Vault RIM is part of Veeva
Development Cloud
, a unified suite of applications for clinical,
regulatory, and quality to help organizations drive end-to-end business
processes across R&D and manufacturing.

In other news today, Veeva announced the continued momentum for Veeva
Vault CTMS
among customers to unify clinical information and
processes. Read the Vault
CTMS news
to learn.

Also, be sure to join 1,300 life sciences professionals and experts at
the upcoming Veeva
R&D Summit
in Philadelphia, September 16-18. Learn more,
register, and view the full agenda at

Additional Information

For more on Veeva Vault Submissions Publishing, visit:
with Veeva on LinkedIn:
@veevasystems on Twitter:
Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 650 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices throughout
North America, Europe, Asia, and Latin America. For more information,

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva's products and services, the results
from use of Veeva's products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva's historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva's expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva's financial results are included under the captions,
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," in the company's filing on Form
10-K for the period ended April 30, 2018. This is available on the
company's website at
under the Investors section and on the SEC's website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

View Comments and Join the Discussion!